StockMirror — Stock Screener

KIMS Q2 FY27 Results & Earnings Analysis

Sentiment: Good (Confidence: high)

Earnings Summary

KIMS Hospitals reported strong Q2 FY27 results with consolidated revenue of INR1,363 crores (+41.3% YoY, +14% QoQ), EBITDA of INR279 crores (+34% YoY, +16.3% QoQ), and PAT of INR76 crores (vs INR37 crores QoQ, INR72 crores YoY). EBITDA margin at 20.5% represents a 120 bps YoY decline primarily due to new hospital fixed costs and one-time doubtful debt provisions but management guided Q2 as the bottom with upward trajectory expected. Volume growth was strong with IP volumes +27% YoY and OP volumes +23.3% YoY. The company completed multiple acquisitions (KIMS Trust Hospital Kakinada 51% for INR80 cr, Ushahkal Abhinav Sangli 6% for INR15 cr) and O&M agreements (Arete Gachibowli 300 beds, Westfort Thrissur 300 beds). Kondapur new hospital ramped exceptionally with 70% revenue growth in 3 months at 70-75% occupancy. Capex of INR650 crores spent in H1 with ~INR1,100 crores planned over next 18 months. Net debt at INR2,150 crores (1.9x EBITDA) post QIP. Key risks include regulatory pricing changes (trade margin rationalization on anti-cancer drugs, Kerala private hospital regulation) and insurance empanelment delays, though these appear manageable.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management explicitly targeting growth through new hospital ramp-ups, acquisitions, and O&M expansion while expecting margin recovery as new units stabilize; stated Q2 is bottom for margins with upward trajectory expected, targeting 30% margins at Telangana and 20%+ consolidated . Company is investi

About Krishna Institute of Medical Sciences Limited

Krishna Institute of Medical Sciences Limited (KIMS) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More